Director Melissa B. Epperly Sells $196K of Roivant Sciences ($ROIV) via 10b5-1 Plan

Executive Summary

On September 17, 2026, Roivant Sciences Ltd. (ROIV) filed a Form 4 reporting open-market dispositions of Common Shares by Director Melissa B. Epperly. The transactions occurred on September 15, 2026, and involved the sale of 4,938 Common Shares at a weighted average price of approximately $39.74 per share, resulting in total proceeds of $196,229.70.

Transaction Breakdown

The aggregate disposition was executed in two blocks:

1. 4,338 shares sold at a weighted average price of $39.65 (price range: $39.25 to $40.15).
2. 600 shares sold at a weighted average price of $40.38 (price range: $40.25 to $40.50).

Following these transactions, Melissa B. Epperly directly retains 9,900 Common Shares of Roivant Sciences Ltd.

Plan and Governance Context

Both transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on March 30, 2026. Because the sales were carried out under a trading plan adopted nearly six months prior, the timing does not reflect opportunistic trading or discretionary reaction to near-term material non-public information.

Market Impact & Significance

• Significance Level: Low
• The aggregate transaction value of under $200,000 represents a relatively small volume relative to Roivant's typical market liquidity.
• The execution under a Rule 10b5-1 plan further limits any negative signaling typically associated with insider sales.